A phase 2b/3 study of BPS-804 for the treatmetn of osteogenesis imperfecta in paediatric patients.
Phase of Trial: Phase II/III
Latest Information Update: 17 Dec 2018
At a glance
- Drugs Setrusumab (Primary)
- Indications Osteogenesis imperfecta
- Focus Adverse reactions; Therapeutic Use
- 17 Dec 2018 According to a Mereo BioPharma media release, study design has been approved by the EMA.
- 23 Mar 2018 According to a Mereo BioPharma media release, the company intends to commence this Phase 2b/3 clinical trial in the second half of 2018.
- 14 Dec 2017 According to a Mereo BioPharma media release, company has recently submitted its Paediatric Investigation Plan (PIP) for BPS-804 to the Paediatric committee of the European Medicines Agency (PDCO) to initiate this clinical trial.